Brain structural and microstructural differences are phenotypically associated with 1 many other complex traits across different categories, such as cognitive measures 1-5 , 2 neurodegenerative/neuropsychiatric traits [6] [7] [8] [9] , alcohol and tobacco consumption 10 , and 3 physical bone density 11 . Structural variations of human brain can be quantified by 4 multimodal magnetic resonance imaging (MRI). Specifically, the T1-weighted MRI 5 (T1-MRI) can provide basic morphometric information of brain tissues, such as volume, 6 surface area, sulcal depth, and cortical thickness. In region of interest (ROI)-based 7 T1-MRI analysis, images are annotated onto ROIs of pre-defined brain atlas, and then 8 both global (e.g., whole brain, gray matter, white matter) and local (e.g., basal ganglia 9 structures, limbic and diencephalic regions) markers can be generated to measure the 10 brain anatomy. On the other hand, diffusion MRI (dMRI) can capture local tissue 11 microstructure through the random movement of water. Using diffusion tensor imaging 12 (DTI) models, brain structural connectivity can be quantified by using white matter 13 tracts extracted from dMRI, which build psychical connections among brain ROIs and are 14 involved in connected networks for various brain functions 12, 13 . See Miller, et al. 11 and 15 Elliott, et al. 14 for a global overview and more information about neuroimaging 16 modalities used in the present study. 17 18 Structural neuroimaging traits have shown moderate to high degree of heritability in 19 both twin and population-based studies [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . In the past ten years, genome-wide 20 association studies (GWAS) 3, 14, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] have been conducted to identify the associated 21 genetic variants (typically single-nucleotide polymorphisms [SNPs]) for brain structures. 22
A highly polygenic 34, 35 genetic architecture has been observed, indicating that a large 23 number of genetic variants contribute to the brain structure variations measured by 24 neuroimaging biomarkers 21, 36 . Particularly, using data from the UK Biobank (UKB 39 ) 25 cohort, two recent large-scale GWAS have identified 578 associated genes for 101 26 regional brain volumes derived from T1-MRI 37 (referred as ROI volumes, n=19,629) and 27 110 DTI parameters of dMRI 38 (referred as DTI parameters, n=17, 706) . Some of these 28 discovered genes had been implicated with the same or other traits such as cognition 29 and mental health diseases/disorders in previous GWAS. However, most of them have 30 not been verified and need further investigations. As a supplement to traditional GWAS, 31 recent advances of gene expression imputation methods [40] [41] [42] [43] [44] [45] [46] and developments of 32 reference databases (e.g., the Genotype-Tissue Expression (GTEx) project 47 ) have put 1 the transcriptome-wide association studies (TWAS) forward for gene-trait association 2 analysis. Despite some challenges 48 such as interpreting causality, TWAS has successfully 3 discovered novel gene-trait associations and provided new insights into biological 4 mechanisms for many complex traits 49 . Through imputed transcriptomes, TWAS can 5 reduce the multiple testing burden and leverage gene expression data to increase 6 testing power for gene-trait association detection. This is a particularly desirable feature 7 for imaging genetics studies, for which most of neuroimaging GWAS datasets continue 8 to have small sample sizes and heavy multiple testing burden 50 . 9 10 Here we applied TWAS methods to 211 structural neuroimaging traits including 101 ROI 11 volumes and 110 DTI parameters. As these brain-related traits tend to be highly 12 polygenic 21, 36 and are related with many traits across different categories 11 , we used a 13 cross-tissue (panel) TWAS approach (UTMOST 42 ) in our main analysis. UTMOST first 14 performs single-tissue gene-trait association analysis in each reference panel with both 15 within-tissue and cross-tissue statistical penalties, and then combines these single-tissue 16 results using the Generalized Berk-Jones (GBJ) test 51 , which is aware of 17 tissue-dependence and can account for the potential sharing of local expression 18 regulation across tissues. The UKB dataset was used in the discovery phase (n=19,629 19 for ROI volumes and 17,706 for DTI parameters, respectively). For the same UKB cohort, 20 we compared TWAS-significant genes to previous GWAS findings in gene-based 21 association analysis via MAGMA 52 and gene-level functional mapping and annotation 22 results by FUMA 53 . The UKB TWAS results were validated in five independent data 23 sources, including Philadelphia Neurodevelopmental Cohort (PNC 54 ,n=537), Alzheimer's 24 Disease Neuroimaging Initiative (ADNI 55 , n=860), Pediatric Imaging, Neurocognition, and 25 Genetics (PING 56 , n=461), the Human Connectome Project (HCP 57 , n=334), and the 26 ENIGMA2 24 and ENIGMA-CHARGE collaboration 33 (n=13, 193, for 8 ROI volume traits, 27 referred as ENIGMA in this paper). Additional TWAS analysis was performed on 11 28 cognitive and mental traits to explore their genetics overlaps with brain structures. 29
Chromatin interaction enrichment analysis and drug-target lookups were conducted for 30 TWAS-significant genes. Finally, we developed TWAS gene-based polygenic risk scores 58 31 (PRS) using FUSION 40 to fully assess polygenic architecture and examine the predictive 1 ability of the UKB TWAS results. 2 3 RESULTS 4
Overview of TWAS discovery-validation in the six datasets 5
We conducted a two-phase discovery-validation TWAS analysis for 211 neuroimaging 6 traits by using the UKB cohort for discovery and the other datasets (ADNI, HCP, PING, 7 PNC, and ENIGMA) for validation. We applied the UTMOST gene expression imputation 8 models trained on 44 GETx (v6) reference panels, and used GWAS summary statistics 9 generated from previous GWAS as inputs. In the rest of this paper, we refer 1.37*10 -8 10 (that is, 5*10 -2 /17,290/211, adjusted for all candidate genes and traits performed) as 11 the significance threshold for gene-trait associations unless otherwise stated. 12
13
The UKB discovery phase identified 614 significant gene-trait associations 14
( Supplementary Table 1 ) between 204 genes and 135 neuroimaging traits (53 ROI 15 volumes, 82 DTI parameters) . Of the 204 TWAS-significant genes, 61 (29.9%) had 16 significant associations with more than two neuroimaging traits, 25 (12.3%) had more 17 than five significant associations, and 12 (5.9%) had at least ten, including OSER1, XRCC4, 18 PLEKHM1, ZKSCAN4, EIF4EBP3, MAPT, LRRC37A, CRHR1, FOXF1, TREH, ARHGAP27, and 19 C6orf100. These 12 genes together contributed 195 (31.8%) of the 614 gene-trait 20 associations, indicating their widespread influences on brain structures. Specifically, we 21 identified 123 genes whose imputed gene expression levels were significantly associated 22 with one of more of the 53 ROI volumes (215 associations in total, 115 new, 23 Supplementary Fig. 1 ), and 103 significantly associated genes (22 overlapping) for one 24 or more of the 82 DTI parameters (399 associations in total, 219 new, Supplementary 25 Figure 1 illustrates that TWAS prioritized previous GWAS findings of MAGMA and 26 FUMA and also discovered many new associations and genes. Moreover, some genes 27 were associated with both ROI volumes and DTI parameters, while others were more 28 specifically related to certain structures (Supplementary Fig. 3 ). For example, XRCC4, 29 ZKSCAN4, EIF4EBP3, and CD14 were associated with DTI parameters but not ROI 30 volumes, DEFB124, COX4I2, HCK, HM13, and REM1 showed associations with putamen 31 and pallidum volumes, and the associations of PLEKHM1, LRRC37A, MAPT, CNNM2, 32 The other 86 genes had not been linked to brain structure previously and thus can be 23 regarded as novel genes for these 211 neuroimaging traits. To explore the genetic 24 overlaps with other traits in different domains, we performed association lookups for 25 the 90 TWAS-significant genes on the NHGRI-EBI GWAS catalog (Supplementary Table  26 8). Figure 2 shows that these genes were widely associated with physical measures (e.g., 27
height, waist-to-hip ratio, heel bone mineral density, body mass index), cognitive traits 28 (e.g., cognitive function, intelligence, math ability), neuropsychiatric and 29 neurodegenerative diseases/disorders (e.g., schizophrenia, bipolar disorder, Alzheimer's 30 disease), coronary artery disease, mean corpuscular hemoglobin, neuroticism, 31 education, reaction time, chronotype, smoking behavior and alcohol use, such as 1 CDK2AP1 [64] [65] [66] [67] and SH2B1 72, [74] [75] [76] . 2 3 For the 18 TWAS-validated genes shown in Supplementary Fig. 4 , 8 (ANKRD42, DCC, 4 LRRC37A, NUP210L, DOK5, C20orf166 , and DPP4) of them had been 5 discovered in the previous UKB GWAS and were implicated in brain-related complex 6 traits, such as neuroticism 64 , major depression 77 , schizophrenia 78-80 , Intelligence 81 , math 7 ability 73 , reaction time 75 , and insomnia 82 . The left ten genes, which were novel findings 8 of TWAS, also had known associations with many cognitive and mental health traits. For 9 example, previous GWAS reported that HCK was associated with chronotype 82 , LGALS3 10 with schizophrenia 83 , UBE2C with reaction time 75 , KLRD1 with adolescent idiopathic 11 scoliosis 84 , OSER1 with cognitive performance 77 and Alzheimer's disease 76 , and PRPF3 12 with chronotype 76,85 and neuropsychiatric disorders 86 . In summary, TWAS novel and 13 validated genes expand the overview of gene-level pleiotropy across these traits, 14
suggesting that neuroimaging-derived biomarkers could be useful in studying a wide 15 range of complex traits. 16 17 Compared to brain tissue-specific TWAS analysis 18
As a comparison, we performed a brain tissue-specific version of TWAS that only 19 combines brain tissues in UTMOST (Method). This brain tissue-specific TWAS detected 20 308 significant gene-trait associations ( Supplementary Table 9 ) between 107 unique 21 genes and 96 neuroimaging traits, including 64 associated genes for one or more of 37 22 ROI volumes (104 associations, Supplementary Fig. 7) , and 53 genes (10 overlapping) for 23 one or more of 59 DTI parameters (204 associations, Supplementary Fig. 8 ). 24 25 Most (101/107) of the tissue-specific genes have been identified by either the 26 cross-tissue TWAS (95/107) or previous GWAS (70/107). The 6 genes that were uniquely 27 identified by tissue-specific analysis included KNCN, LHFPL3, MBD2, TBK1, C3orf62, and 28 TMEM173. LHFPL3 showed associations with education 87 , social behavior 88,89 , cognitive 29 ability 75 , schizophrenia 90 , and bipolar disorder 91 . MBD2 was associated with reaction 30 time 75 , TBK1 with amyotrophic lateral sclerosis 92,93 , and C3orf62 with intelligence 82 . 31
Compared to tissue-specific TWAS, cross-tissue analysis clearly identified more signals. 32
For example, of the 215 gene-trait associations identified by cross-tissue analysis of ROI 1 volumes, 100 had been identified in GWAS, 28 can be additionally identified by 2 tissue-specific TWAS, and 87 can only be detected by cross-tissue analysis 3 ( Supplementary Fig. 9) . Similarly, 180 of the 399 cross-tissue TWAS associations for DTI 4 can be identified in GWAS, 69 can be additionally identified by tissue-specific TWAS, and 5 150 were cross-tissue TWAS only (Supplementary Fig. 10) . These results illustrate the 6 advantage of cross-tissue analysis over brain tissue-specific TWAS for discovering 7 association signals that are difficult to be identified in traditional GWAS. We further 8 compared their results in a few follow-up analyses below. 9 10
Comparison with GWAS variant-level signals and conditional analysis 11
For each of the 614 gene-trait associations detected in cross-trait TWAS, we used 12 previous GWAS summary statistics to check the most significant variant within the gene 13 region (with a 1MB window on each side) that was pinpointed in the same UKB dataset 14 (Method). The GWAS p-value of the most significant variant was greater than 1*10 -6 for 15 any associations of 13 genes ( Supplementary Table 10 ). None of them had been 16 identified by MAGMA or FUMA, indicating that it can be difficult to detect these genes 17 by GWAS or post-GWAS screening for any of these neuroimaging traits. Of the 13 genes, 18 7 (OSER1, TREH, PRPF3, KLRD1, TGM7, DCTPP1, UBE2C) were validated in one or more 19 of the five validation datasets and were discussed in previous section. For the other 6 20 genes (CELSR3, MYO9A, DNAJC24, GYPE, TMEM136, MOB4) genes, MOB4 was reported 21 for major depression 94 and autism spectrum disorder/schizophrenia 95 , DNAJC24 was 22 linked to adolescent idiopathic scoliosis 84 , and CELSR3 was associated with education 65 23 and cognitive ability 64,81 . The same checking was then performed for the 308 significant 24 gene-trait associations of brain tissue-specific TWAS. We found that only one gene 25 DCTPP1 had minimum GWAS p-value greater than 1*10 -6 ( Supplementary Table 11 ). 26
27
We next performed a conditional analysis to see whether the TWAS signals remained 28 significant after adjustment for the most significant genetic variant used in UTMOST 29 gene expression imputation models (Method). Although our cross-tissue analysis 30 combined information from many genetic variants across various human tissues, we 31 found that 418 of the 614 associations may indeed be dominated by the strongest 32 GWAS signal of the imputation model, as their conditional p-values were larger than 1 0.05 ( Supplementary Table 12 ). However, the conditional p-values of four genes (XRCC4, 2 OBFC1, C15orf56, NMT1) were smaller than 1*10 -6 for 18 gene-trait associations, 3 suggesting that these associations were unlikely to be driven by a signal genetic variant. 4
When the p-value threshold was relaxed to 1*10 -3 , 66 associations of 20 genes persisted 5 after conditional analysis. The conditional analysis was also performed on significant 6 associations of brain tissue-specific TWAS. Their conditional p-values were smaller than 7 1*10 -6 for three genes (XRCC4, C15orf56, NMT1) with 15 associations, and were smaller 8 than 1*10 -3 for 10 genes with 42 associations ( Supplementary Table 13 ). 9 10 Additional TWAS analysis for cognitive and mental health traits 11
To further explore the gene-level genetic overlaps among brain structure and other 12 brain-related traits, we performed cross-tissue TWAS analysis for 11 cognitive and 13 mental health traits ( Supplementary Table 14 ). We found that 69 of the 204 14 TWAS-significant genes of neuroimaging traits were also significantly associated with 15 one or more of the 11 cognitive and mental health traits (Figure 3) . These results 16 suggest the genes involved in brain structure changes are often also active in brain 17 functions and mental disorder/diseases. For example, we found 33 overlapping genes 18 with cognitive function, 32 with education, 26 with numerical reasoning, 25 with 19 intelligence, 23 with neuroticism, 19 with drinking behavior, and 13 with schizophrenia. 20 A large proportion (48/69) of these genes were associated with more than one cognitive 21 or mental health traits, and 11 genes were linked to at least five traits, including SCML4, 22
C16orf54, DCC, NFATC2IP, NPIPB7, NPIPB9, SH2B1, CRHR1, LRRC37A, HIST1H2BO, and 23 NKAPL, indicating the high degree of statistical pleiotropy 96 of these genes. 24 25
Chromatin interaction enrichment analysis and drug-target lookups 26
To explore the biological interpretations of TWAS and GWAS-significant genes, we 27 performed enrichment analysis in promoter-related chromatin interactions of four types 28 of brain neurons 97 (iPSC-induced excitatory neurons, iPSC-derived hippocampal DG-like 29 neurons, iPSC-induced lower motor neurons, and primary astrocytes), and also in high 30 confident interactions of adult and fetal cortex 98 (Method). The raw p-values of 31
Wilcoxon rank test for enrichment were summarized in Supplementary Table 15 . We 32 found that cross-tissue TWAS-significant genes of the 11 cognitive and mental health 1 were significantly enriched in chromatin interactions from all of the five validation 2 datasets (p-value range=[4.91*10 -11, 3.03*10 -5 ]), suggesting that TWAS-significant genes 3 actively interacted with other chromatin regions and played a more important role in 4 regulating gene expressions as compared with other genes. The cross-tissue 5 TWAS-significant genes of neuroimaging traits also showed significant enrichments 6 (p-value range= [1.38*10 -3 ,2.44*10 -2 ]). Merging the two sets of genes resulted in smaller 7 p-value in each dataset (p-value range=[2.93*10 -11, 2.77*10 -5 ]). The most significant 8 enrichment was observed in iPSC-induced lower motor neurons. These results remained 9 significant after adjusting for multiple testing by using Benjamini-Hochberg (B-H) 10 procedure at 0.05 level ( Supplementary Table 16 ). In contrast, GWAS-significant genes 11 were only significantly enriched in primary astrocytes and high confident interactions 12 (p-value range=[5.11*10 -3, 1.48*10 -2 ]), and brain tissue-specific TWAS-significant genes 13 did not show any significant enrichments after B-H adjustment. 14
15
We carried out drug-target lookups using a recently published drug-target database 99 to 16 see whether any of the TWAS and GWAS-significant genes were known targets of 17 existing drugs. We focused on nervous system drugs with Anatomical Therapeutic 18 Chemical (ATC) code started with "N", yielding 2,285 drug-gene pairs between 273 19 drugs and 241 targeted genes. We found that 12 TWAS-significant genes of the 11 20 cognitive and mental health traits were known targets for 64 drugs, including CACNA1I, 21 ESR1, ALDH2, CACNA1C, GRM2, KCNJ3, SCN3A, CACNA1D, KCNK3, CHRNA3, CHRNA6, 22 and SLC6A4. Of the 64 drugs, 27 were anti-depressants (ATC: N06A) to treat major 23 depressive disorder and other conditions, and 10 were anti-psychotics (ATC: N05A) to 24 manage psychosis such as schizophrenia and bipolar disorder ( Supplementary Table 17) . 25
In addition, 3 more drug-target genes (GABBR1, HTR2B, CREB1) were detected by GWAS 26 or TWAS of neuroimaging traits ( Supplementary Table 18 ). These 3 genes were 27 targets for 19 more drugs, 6 of which were anti-Parkinson drugs (ATC: N04) for 28 treatment of Parkinson's disease and related conditions, and 5 were anti-migraine 29 preparations (ATC: N02C) used in prophylaxis and treatment of migraine. These results 30 may suggest that TWAS-significant genes could be considered as new targets in future 31 drug development. 32 1
TWAS gene-based polygenic risk scores analysis 2
To fully assess the polygenic genetic architecture of neuroimaging traits and examine 3 the predictive ability of UKB TWAS results, we constructed TWAS gene-based PRS on 4 subjects in PNC, HCP, PING, and ADNI cohorts for all of the 211 neuroimaging traits 5 (Method). The prediction analysis was conducted separately on 52 reference panels (13 6 GETx v7 brain tissues, 35 GTEx v7 other tissues, 1 non-GETx brain tissue, and 3 non-GETx 7 other tissues) using the FUSION 40 software and database. We found that genetically 8 predicted profiles for 28 ROI volumes ( Figure 5 ) and 23 DTI parameters (Supplementary 9 Fig. 11 ) were significantly associated with the corresponding observed traits in all 10 testing datasets after Bonferroni correction (that is, 101*4+3*110=734 tests). Compared 11 to previous SNP-based PRS analysis that yielded significant PRS profiles for 11 ROI 12 volumes 37 , gene-based PRS profiles were significant for more ROI volumes, such as 13 left/right insula, left/right pallidum, left/right ventral DC, left/right fusiform, and 14 left/right transverse temporal, suggesting the substantial power gain in association 15 analysis of PRS. The significant TWAS PRS can account for 0.97%-6.97% phenotypic 16 variance (p-value range=[8.0*10 -29 , 6.81*10 -5 ]) ( Supplementary Tables 19-20) , which 17 was within the similar range to SNP-based PRS analysis. For example, the (incremental) 18 R-squared of TWAS PRS of Cerebellar vermal lobules VIII-X was 6.97% in PNC and 6.48% 19 in HCP, and the R-squared of SFO MD-derived TWAS PRS was 3.8% in PING and 2.41% in 20 PNC. We also examined the performance of each reference panel on these significant 21 traits. There was a significant linear relationship between the panel sample size and 22 average prediction R-squared (48 GTEx reference panels, simple correlation=0.53, 23 p-value=1.21*10 -4 , Supplementary Fig. 12 ), which means that currently panel sample 24 size may dominate the performance of TWAS PRS analysis regardless of the tissue 25 specificity 58 . Among the brain tissue panels, we found that cerebellum tissue had the 26 largest sample size and also showed the highest average R-squared (Supplementary 27 In this study, we applied TWAS methods on 211 neuroimaging traits to identify genes, 31 whose imputed expression levels were associated with brain structure variations. Using 32 a cross-tissue approach, our main discovery analysis identified 86 novel genes and 1 validated 18 significant genes at stringent Bonferroni-correction p-value thresholds. 2 Conditional analysis and comparison with GWAS variant-level results suggested that the 3 identification and validation of new genes reflect the ability of TWAS to reduce the 4 testing burden and to combine the small genetic variant effects. We also performed 5 brain tissue-specific TWAS and illustrated the unique strengths of cross-tissue TWAS in 6 conditional and enrichment analyses. Lots of brain structure-related genes were known 7 genetic factors for a wide range of complex traits, ranging from physical traits, cognition, 8 mental disease/disorders, blood assays, to lifestyle, which extend the potential 9 applications of neuroimaging traits. Some of these genetic overlaps were additionally 10 highlighted by a TWAS analysis of 11 cognitive and mental health traits. 11
12
The present study faces some limitations. First, since these results are purely based on 13 statistical associations, it is hard to draw conclusions about the underlying causality and 14 prioritize causal genes 42,100 . This is also one of the main challenges for most of the 15 current TWAS approaches 48 . Follow-up experimental validation is a clear need to 16 confirm TWAS results and pinpoint the causal genes of brain structure changes. Second, 17 the brain tissue-specific TWAS did not yield much new results compared to the previous 18 GWAS and brain tissue panels did not show better prediction accuracy than non-brain 19 tissues in gene-based PRS analysis. Both of the two observations support the use of 20 multiple tissues in our analysis to increase testing power for association analysis, but 21 making the causality interpretation of TWAS results even more complicated. In addition, 22 though gene-based PRS had much better power in association tests than SNP-based 23 polygenic scores, their prediction accuracies were similar. These limitations may be due 24 to the fact that currently brain tissue reference panels do not have large sample size 25 and/or the associated gene expression imputations may have low quality. Despite these 26 limitations, it is clear that TWAS have the potential to become a powerful supplement to 27 traditional GWAS in imaging genetics studies. In our study, many new gene-trait 28 associations were discovered and the underlying genetic overlaps among complex traits 29 were largely expanded. With better brain tissue gene expression reference panels and 30 more neuroimaging GWAS datasets available, future TWAS analyses of neuroimaging 31 traits are expected to show the value of tissue specificity and improve our 1 understanding for the genetic basis of human brain. 2 3 ACKNOWLEDGEMENTS 4
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Part of data collection and sharing for this project was funded by the Alzheimer's 13 169-181 (2019) . For discovery, we used the GWAS summary statistics of the UKB study. Then the GWAS 17 results of the other studies were used for validation, see Supplementary Table 22 for a 18 summary of sample size and the analyzed neuroimaging traits of each GWAS. More 19 information about study cohorts and neuroimaging traits can be found in the original 20 GWAS 24, 33, 37, 38 . We also performed TWAS analysis for 11 cognitive and mental health 21 traits, see Supplementary Table 23 for these data resources. 22 23
Cross-tissue TWAS analysis by UTMOST 24
Cross-tissue TWAS analysis was performed for each trait using the UTMOST software 25 (https://github.com/Joker-Jerome/UTMOST). We first run single-tissue association test 26 for each of the 44 GTEx (v6) reference panels using the above GWAS summary statistics 27 as input. There were 17,290 candidate genes considered in UTMOST. Second, the 28 gene-trait associations in 44 panels (tissues) were combined by the GBJ test 29 (https://cran.r-project.org/web/packages/GBJ/). We used the pre-trained cross-tissue 30 imputation models and pre-calculated covariance matrices provided by UTMOST. For 31 the 211 neuroimaging traits in the UKB cohort, we also performed a brain-tissue specific 1 version of UTMOST analysis that only combined brain tissues. 2 3 Comparison with previous GWAS findings 4
We compared TWAS-significant genes with those identified in the same UKB cohort by 5 MAGMA gene-based association analysis and FUMA functional gene mapping analysis, 6 which can be found in previous GWAS ( Supplementary Tables 12 and 15 for ROI volumes and Supplementary Tables 14 and 16 of Zhao, et al. 38 for DTI 8 parameters, respectively). For each significant gene-trait association, we also explored 9 whether any genetic variant of this gene region (with 1MB window on both sides) had 10 been linked to this neuroimaging trait by checking the smallest p-value in corresponding 11 GWAS. For TWAS-significant genes that were not identified in GWAS, we used 12 NHGRI-EBI GWAS catalog (version 2019-10-14, https://www.ebi.ac.uk/gwas/) to look for 13 their reported associations with brain structure traits and any other traits. We 14 summarized the traits that frequently reported for these genes, such as physical 15 measures (e.g., height, waist-to-hip ratio, heel bone mineral density, body mass index), 16
cognitive functions (such as general cognitive ability, cognitive performance), 17 intelligence, educational attainment, math ability (such as highest math class taken and 18 self-reported math ability), reaction time, neuroticism, neurodegenerative diseases 19 (such as Alzheimer's disease and Parkinson's disease), neuropsychiatric disorders (such 20 as major depressive disorder, schizophrenia, and bipolar disorder), coronary artery 21 disease, and mean corpuscular hemoglobin. 22 23
Cross-tissue analysis conditional on the most significant GWAS signal 24
The TWAS gene expression imputation model can be viewed as a weighted sum of 25 multiple genetic variants. If certain variant has a relatively large weight, the imputed 26 gene expression could be driven by a single GWAS signal. In order to look at how many 27 significant TWAS signals could be dominated by a single genetic variant, we rerun TWAS 28 analysis in UKB cohort conditional on the most significant variant used in the UTMOST 29 imputation model. First, for each reference panel, we considered a simple linear model 30
Phenotype ~ imputed gene expression + variant, 31
where the variant conditioned on was the most significant variant in previous GWAS of 1 this phenotype in the same UKB cohort. Then, single-tissue conditional p-values of the 2 imputed gene expression were combined by the GBJ test across the 44 GTEx reference 3 panels. 4 5 Enrichment analyses and drug-target lookups 6
The chromatin interaction enrichments between significant and non-significant genes 7 were tested using the Wilcoxon rank sum test. For the adult neural Promoter Capture 8
Hi-C (PCHi-C), the enrichment of each gene was measured as the number of interactions 9 overlapping gene with CHiCAGO Enrichment Score greater than 5 97 . The enrichment was 10 tested separately in four cell types, including induced pluripotent stem cells 11 (iPSC)-induced excitatory neurons, iPSC-derived hippocampal DG-like neurons, 12 iPSC-induced lower motor neurons, and primary astrocytes. For the high confident 13
interactions of adult and fetal cortex, the enrichment of each gene was measured as the 14 sum of -log10(P-value) of all significant interactions overlapping the gene 98 . The 15 drug-target lookups were conducted using the drug-gene associations reported in Wang, 16 et al. 99 . We focused on nervous system drugs whose Anatomical Therapeutic Chemical 17 code starts with "N" according to the DrugBank database (version 2019-07-02, 18 https://www.drugbank.ca/atc). 19 20
Gene-based TWAS polygenic risk prediction 21
Gene-based polygenic profiles were created to assess the out-of-sample prediction 22 power of the UKB TWAS results. In this analysis, we used the individual-level phenotype 23 and genetic data, whose processing steps were detailed in previous GWAS 37,38 . The 24 FUSION software and database (http://gusevlab.org/projects/fusion/) were used to 25 impute gene expression levels in UKB, ADNI, HCP, PNC, and PING datasets using 26 individual-level genetic data. We performed imputation for 52 different reference 27 panels ( Supplementary Table 21 ). In training data (UKB), we estimated the effect size of 28 each imputed gene expression in a linear regression model, while adjusting for the age 29 (at imaging), age-squared, sex, age-sex interaction, age-squared-sex interaction, as well 30 as the top 40 genetic principle components (PCs) provided by UKB 101 (Data-Field 22009). 31
For ROI volumes, we also included total brain volume (for ROIs other than total brain 32 volume itself) as a covariate. The gene-based PRS were generated in testing data by 1 summarizing across imputed gene expressions, weighed by their effect sizes estimated 2 from the training data. We tried a series of p-value thresholds for predictor selection: 1, 3 0.8, 0.5, 0.4, 0.3, 0.2, 0.1, 0.08, 0.05, 0.02, 0.01, 0.001, 1*10 -4 , 1*10 -5 , 1*10 -6 , 1*10 -7 , and 4 5*10 -8 . Thus, seventeen polygenic profiles were generated for each neuroimaging traits 5 and we reported the best prediction power that can be achieved by a single profile of 6 them in the single reference panel. The association between polygenic profile and trait 7 was estimated and tested in linear regression model, adjusting for the effects of age and 8 sex. The additional phenotypic variation that can be explained by polygenic profile (i.e., 9 the incremental R-squared) was used to measure the prediction power. 10 11
Data availability 12
The individual-level data used in this work was obtained from five publicly available 13 datasets: the UK Biobank (UKB) study, the Human Connectome Project (HCP) study, the 14 Pediatric Imaging, Neurocognition, and Genetics (PING) study, the Philadelphia 15
Neurodevelopmental Cohort (PNC) study, and the Alzheimer's Disease Neuroimaging 16
Initiative (ADNI) study. The GWAS summary statistics of UKB study have been shared at 17 https://github.com/BIG-S2/GWAS, and the summary statistics of other validation 18 datasets will also be shared at https://github.com/BIG-S2/GWAS upon acceptance of 19 this paper. We also used the summary-level data of ENIGMA2 and ENIGMA-CHARGE 20 collaboration, which can be obtained at http://enigma.ini.usc.edu/research/. In addition, 21 we used other 11 sets of publicly available GWAS summary statistics shared by several 22 GWAS databases. These data resources were summarized in Supplementary Table 23 . 23 24
Code availability 25
We made use of publicly available software and tools, especially the UTMOST 26 The gene-level associations were estimated and tested by the cross-tissue UTMOST 4 approach (https://github.com/Joker-Jerome/UTMOST). We used the p-value threshold 5 of 1.37*10 -8 , corresponding to adjusting for testing 211 imaging phenotypes with the 6 Bonferroni correction. The x axis provides the IDs of the neuroimaging traits, and the y 7 axis lists the detected genes in TWAS. The new (UTMOST new) and previously reported 8 GWAS-significant associations (MAGMA, FUMA, and FUMA&MAGMA) were labeled with 9 different colors (orange, purple, green, and red, respectively). The gene-level associations were estimated and tested by the cross-tissue UTMOST 24 approach (https://github.com/Joker-Jerome/UTMOST). We adjusted for testing 211 25 neuroimaging traits (p-value threshold 1.37*10 -8 ) and 11 cognitive traits (p-value 26 threshold 2.63*10 -7 ) with the Bonferroni correction, respectively. The x axis provides the 27 IDs of the neuroimaging traits. The y axis lists the 11 cognitive and mental health traits, 28
and Supplementary Table 23 
